Meghmani Organics Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - CAPEX plans are being carefully calibrated, with some expansion projects on hold due to current market conditions. - Ongoing CAPEX includes Rs. 275 crore spent on the Titanium Dioxide plant, around Rs. 110 crore for cogeneration power plant, and Rs. 150 crore for Meghmani Crop Nutrition Limited projects. - No specific discussion about raising funds via new debt or equity was made during the call.

- Ongoing CAPEX on Titanium Dioxide (TiO2) plant at Kilburn Chemicals: - Phase one completed with Rs. 275 crore already spent. - Captive cogeneration power plant is in final stages, with Rs. 100-110 crore expenditure expected to complete this quarter. - Meghmani Crop Nutrition Limited project: - Total CAPEX estimated at Rs. 150 crore. - Around Rs. 75 crore to be spent by March 2024. - Expansion plans for Agro Phase Two are currently on hold due to market conditions. - Sustenance and maintenance CAPEX expected around Rs. 10-15 crore annually. - Nano Urea plant commissioning planned by end of Q4 FY24, aiming for market presence in next Kharif season. - Overall approach to CAPEX is calibrated with emphasis on completing existing projects before further expansion.

- Recovery expected primarily from agrochemical segment starting FY25 as channel inventory clears and global focus on food security increases. - Pigment segment recovery anticipated around FY26 with profitability expected to return in FY25. - Titanium Dioxide plant targeting ~12,000 tonnes capacity at 75-80% utilization next year, expected to generate Rs. 225-250 crore revenue. - Nano Urea plant commissioning planned by end of Q4 FY24, with sales anticipated from next financial year’s Kharif season. - Domestic market share expected to grow with new products like Nano Urea and Titanium Dioxide, balancing export and domestic revenues. - Margins currently under pressure due to market conditions but expected to improve gradually alongside demand normalization. - Cost control measures in place to navigate the challenging year; expected to help improve performance from second half FY24 onwards.

- The company expects recovery starting from FY25, with agrochemical demand improving first due to channel inventory clearance and increased focus on food security globally. - Pigment business profitability is expected to turn positive in FY25, though normalization might take until FY26 due to ongoing demand pressure. - Margins in both segments are currently under pressure but are anticipated to improve as market dynamics stabilize. - Titanium Dioxide plant revenue is expected around Rs. 225-250 crore at 75%-80% capacity utilization next year, contributing positively. - Nano Urea plant commissioning by end of Q4 FY24 should support growth in the subsequent year. - Cost control measures and inventory optimization are underway to sustain balance sheet strength during this downturn. - Long-term growth prospects remain positive, supported by state-of-the-art infrastructure, backward integration, and diverse product range. - Overall, the management foresees gradual margin and earnings improvement beginning FY25, returning to a double-digit growth trajectory post-stabilization.

The transcript from the Meghmani Organics Limited Q2 FY24 Earnings Call does not explicitly mention the current or expected order book or pending orders details. However, key related insights include: - Demand remains subdued globally with high channel inventory impacting sales. - Recovery is expected from the second quarter of the next financial year (FY25), starting primarily in the agrochemical segment. - Titanium Dioxide plant stabilization is underway, with revenue expected to begin contributing meaningfully from Q4 FY24 onwards. - Market demand pressure continues in pigments, with normalization potentially delayed until FY26. - Management is optimistic about long-term growth once market conditions stabilize, supported by state-of-the-art infrastructure and backward integration. - No specific figures or explicit references to current order book or pending orders were disclosed in the call. For precise order book details, it may be advisable to refer to Meghmani Organics' official financial filings or contact investor relations.